menu
    • menu
    [{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw | Nottingham University Hospitals NHS Trust | Amphia Hospital | St. Antonius Hospital | Deventer Ziekenhuis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Flevoziekenhuis | Franciscus Gast","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atosiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw | Nottingham University Hospitals NHS Trust | Amphia Hospital | St. Antonius Hospital | Deventer Ziekenhuis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Flevoziekenhuis | Franciscus Gast","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw | Nottingham University Hospitals NHS Trust | Amphia Hospital | St. Antonius Hospital | Deventer Ziekenhuis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Flevoziekenhuis | Franciscus Gast"}]

    Find Clinical Drug Pipeline Developments & Deals for Atosiban

    Menu

    Atosiban

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Academisch Medisch Centrum - Universiteit van Amsterdam

                            Country arrow
                            CPhI Korea
                            Not Confirmed

                            Academisch Medisch Centrum - Universiteit van Amsterdam

                            Country arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atosiban

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : ZonMw | Nottingham University Hospitals NHS Trust | Amphia Hospital | St. Antonius Hospital | Deventer Ziekenhuis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Flevoziekenhuis | Franciscus Gast

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 23, 2023

                            Lead Product(s) : Atosiban

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : ZonMw | Nottingham University Hospitals NHS Trust | Amphia Hospital | St. Antonius Hospital | Deventer Ziekenhuis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Flevoziekenhuis | Franciscus Gast

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth